IP Library Granted Patent US 7,135,340
Granted Patent B2
US 7,135,340 · App. 10/289,213 · Granted Nov 14, 2006

Tetrameric antibody complexes for blocking non-specific labeling of antigens

Assignee: Stemcell Technologies Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,135,340
App. No.
10/289,213
Granted
Nov 14, 2006
Kind
B2
Abstract

A method for preventing or inhibiting non-specific binding reactions between a detection reagent and an antigen in an immunological assay is described. The method involves using tetrameric antibody complexes that can bind to the antigen and are comprised of two monoclonal antibodies of a first animal species linked to two monoclonal antibodies of a second animal species that can bind the antibodies of the first animal species. Preferably, the antigen is an Fc Receptor and the method reduces the binding of a detection antibody with Fc receptors present on the surface of many cells.

Claims (8)

1. A method of reducing or inhibiting the non-specific binding of a detection reagent to an antigen in a sample comprising

(i) contacting the sample with a tetrameric antibody complex specific for the antigen, wherein the tetrameric antibody complex comprises (a) two monoclonal antibodies of a first animal species and (b) two monoclonal antibodies of a second animal species that can bind to the antibodies of the first animal species and wherein born the monoclonal antibodies of the first animal species bind to the antigen; and

(ii) contacting the sample with the detection reagent which can bind non-specifically to the antigen,

wherein the binding of the tetrameric complex to the antigen reduces or inhibits the non-specific binding of the detection reagent to the antigen in the sample.

2. The method according to claim 1 wherein the antigen is a cell-surface antigen.

3. The method of claim 1 wherein the antigen is on monocytes.

4. The method according to claim 2 wherein the cell-surface antigen is an Fc receptor.

5. The method according to claim 4 wherein the Fc receptor is CD32, CD16, CD23 or CD69.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2022
From: STEMCELL TECHNOLOGIES CANADA INC.
To: HSBC BANK CANADA
Reel/Frame 060544/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2003
From: WOGNUM, ALBERTUS WERNERUS; LANSDORP, PETER MICHAEL
To: STEMCELL TECHNOLOGIES INC.
Reel/Frame 013780/0785 →
Continuity (2)
Provisional Application 6033106000 · Nov 7, 2001
Related Publication 20030119071A1 · Jun 26, 2003